Media coverage about Rewalk Robotics (NASDAQ:RWLK) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Rewalk Robotics earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave press coverage about the medical device company an impact score of 46.5995585602645 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have impacted Accern’s rankings:
- ReWalk Robotics wins German reimbursement nod for Personal 6.0 exoskeleton (massdevice.com)
- Rewalk Robotics Ltd (RWLK) Receives Consensus Rating of “Hold” from Brokerages (americanbankingnews.com)
- Rewalk Robotics Ltd (RWLK) Expected to Announce Earnings of -$0.22 Per Share (americanbankingnews.com)
- Blockchain Deal Sparks Rally for Penny Stock – Schaeffers Research (press release) (schaeffersresearch.com)
Several equities analysts have commented on the stock. ValuEngine raised shares of Rewalk Robotics from a “strong sell” rating to a “sell” rating in a report on Friday. Piper Jaffray Companies reissued a “buy” rating and issued a $3.00 target price on shares of Rewalk Robotics in a report on Sunday, January 7th. Jefferies Group decreased their target price on shares of Rewalk Robotics from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, November 3rd. Zacks Investment Research lowered shares of Rewalk Robotics from a “buy” rating to a “hold” rating in a report on Thursday, January 4th. Finally, Oppenheimer set a $3.00 target price on shares of Rewalk Robotics and gave the company a “buy” rating in a report on Monday, January 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $2.83.
Rewalk Robotics (NASDAQ:RWLK) last posted its quarterly earnings results on Thursday, November 2nd. The medical device company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.10. Rewalk Robotics had a negative net margin of 346.14% and a negative return on equity of 568.25%. The company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $1.63 million. During the same period last year, the company posted ($0.62) EPS. The firm’s quarterly revenue was up 21.4% compared to the same quarter last year. equities analysts predict that Rewalk Robotics will post -1.14 earnings per share for the current fiscal year.
WARNING: This piece of content was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://sportsperspectives.com/2018/02/03/rewalk-robotics-rwlk-earns-news-impact-rating-of-0-18.html.
Rewalk Robotics Company Profile
ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.
Receive News & Ratings for Rewalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rewalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.